Effects of (2R,6R)-hydroxynorketamine in assays of acute pain-stimulated and pain-depressed behaviors in mice

Ketamine has been shown to produce analgesia in various acute and chronic pain states; however, abuse liability concerns have limited its utility. The ketamine metabolite (2R,6R)-hydroxynorketamine (HNK) has been shown to produce antidepressant-like effects similar to ketamine without abuse liability concerns. (2R,6R)-HNK produces sustained analgesia in models of chronic pain, but has yet to be evaluated in models of acute pain. The present study evaluated the efficacy of acute (2R,6R)-HNK administration (one injection) in assays of pain-stimulated (52- and 56-degree hot plate test and acetic acid writhing) and pain-depressed behavior (locomotor activity and rearing) in male and female C57BL/6 mice. In assays of pain-stimulated behaviors, (2R,6R)-HNK (1–32 mg/kg) failed to produce antinociception in the 52- and 56-degree hot plate and acetic acid writhing assays. In assays of pain-depressed behaviors, 0.56% acetic acid produced a robust depression of locomotor activity and rearing that was not blocked by pretreatment of (2R,6R)-HNK (3.2–32 mg/kg). The positive controls morphine (hot plate test) and ketoprofen (acetic acid writhing, locomotor activity, and rearing) blocked pain-stimulated and pain-depressed behaviors. Finally, the effects of intermittent (2R,6R)-HNK administration were evaluated in 52-degree hot plate and pain-depressed locomotor activity and rearing. Intermittent administration of (2R,6R)-HNK also did not produce antinociceptive effects in the hot plate or pain-depressed locomotor activity assays. These results suggest that (2R,6R)-HNK is unlikely to have efficacy in treating acute pain; however, the efficacy of (2R,6R)-HNK in chronic pain states should continue to be evaluated.

[1]  Zhen-Jia Lin,et al.  The potent analgesia of intrathecal 2R, 6R-HNK via TRPA1 inhibition in LF-PENS-induced chronic primary pain model , 2023, The Journal of Headache and Pain.

[2]  S. Majumdar,et al.  Role of mu opioid receptor (MOR) agonist efficacy as a determinant of opioid antinociception in a novel assay of pain-depressed behavior in female and male mice , 2023, Frontiers in pain research.

[3]  K. Manda,et al.  Intranasal (2R, 6R)‐hydroxynorketamine for acute pain: Behavioural and neurophysiological safety analysis in mice , 2022, Clinical and experimental pharmacology & physiology.

[4]  I. Lucki,et al.  (2R,6R)-hydroxynorketamine (HNK) reverses mechanical hypersensitivity in a model of localized inflammatory pain , 2022, Neuropharmacology.

[5]  I. Lucki,et al.  Antinociceptive and Analgesic Effects of (2R,6R)-Hydroxynorketamine , 2022, The Journal of Pharmacology and Experimental Therapeutics.

[6]  M. Michaelides,et al.  Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search , 2022, Molecular Psychiatry.

[7]  I. Lucki,et al.  Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors , 2022, Psychopharmacology.

[8]  E. Jutkiewicz,et al.  The Buprenorphine Analogue BU10119 Attenuates Drug-Primed and Stress-Induced Cocaine Reinstatement in Mice , 2021, The Journal of Pharmacology and Experimental Therapeutics.

[9]  Kathryn E. Livingston,et al.  Positive allosteric modulation of the mu-opioid receptor produces analgesia with reduced side effects , 2021, Proceedings of the National Academy of Sciences.

[10]  T. Gould,et al.  Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications , 2021, Pharmacological Reviews.

[11]  S. Abdi,et al.  Ketamine Use for Cancer and Chronic Pain Management , 2021, Frontiers in Pharmacology.

[12]  M. Morgan,et al.  'Reinventing the wheel' to advance the development of pain therapeutics. , 2020, Behavioural pharmacology.

[13]  T. Hillhouse,et al.  What role does the (2R,6R)‐hydronorketamine metabolite play in the antidepressant‐like and abuse‐related effects of (R)‐ketamine? , 2019, British journal of pharmacology.

[14]  S. Negus,et al.  Effects of repeated treatment with monoamine-transporter-inhibitor antidepressants on pain-related depression of intracranial self-stimulation in rats , 2019, Psychopharmacology.

[15]  T. Patton,et al.  Effects of monoamine uptake inhibitors on pain-related depression of nesting in mice. , 2019, Behavioural pharmacology.

[16]  Yuko Fujita,et al.  Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model , 2019, Behavioural Brain Research.

[17]  S. Thompson,et al.  (R)‐Ketamine exerts antidepressant actions partly via conversion to (2R,6R)‐hydroxynorketamine, while causing adverse effects at sub‐anaesthetic doses , 2019, British journal of pharmacology.

[18]  S. Negus.  Core Outcome Measures in Preclinical Assessment of Candidate Analgesics , 2019, Pharmacological Reviews.

[19]  N. Veronese,et al.  NMDA receptor antagonists and pain relief , 2019, Neurology.

[20]  J. Kroin,et al.  Efficacy of the ketamine metabolite (2R,6R)-hydroxynorketamine in mice models of pain , 2018, Regional Anesthesia & Pain Medicine.

[21]  T. Gould,et al.  Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine , 2018, Journal of psychopharmacology.

[22]  James M. Dahlhamer,et al.  Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016 , 2018, MMWR. Morbidity and mortality weekly report.

[23]  M. Hsieh,et al.  (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray , 2018, Neuropharmacology.

[24]  Steven P. Cohen,et al.  Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists , 2018, Regional Anesthesia & Pain Medicine.

[25]  Yuko Fujita,et al.  Lack of metabolism in (R)-ketamine’s antidepressant actions in a chronic social defeat stress model , 2018, Scientific Reports.

[26]  B. Yawn,et al.  Adverse impacts of chronic pain on health-related quality of life, work productivity, depression and anxiety in a community-based study , 2017, Family practice.

[27]  K. Hashimoto,et al.  Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine , 2017, The international journal of neuropsychopharmacology.

[28]  K. Hashimoto,et al.  (R)-Ketamine Shows Greater Potency and Longer Lasting Antidepressant Effects Than Its Metabolite (2R,6R)-Hydroxynorketamine , 2017, Biological Psychiatry.

[29]  Xi-Ping Huang,et al.  NMDAR inhibition-independent antidepressant actions of ketamine metabolites , 2016, Nature.

[30]  S. Negus,et al.  Effects of the noncompetitive N‐methyl‐d‐aspartate receptor antagonists ketamine and MK‐801 on pain‐stimulated and pain‐depressed behaviour in rats , 2016, European journal of pain.

[31]  S. Negus,et al.  Effects of repeated morphine on intracranial self-stimulation in male rats in the absence or presence of a noxious pain stimulus. , 2015, Experimental and clinical psychopharmacology.

[32]  F. Carroll,et al.  Effects of ketoprofen, morphine, and kappa opioids on pain-related depression of nesting in mice , 2015, Pain.

[33]  W. Carlezon,et al.  Sustained pain-related depression of behavior: effects of intraplantar formalin and complete freund’s adjuvant on intracranial self-stimulation (ICSS) and endogenous kappa opioid biomarkers in rats , 2014, Molecular pain.

[34]  S. Negus,et al.  Expression and treatment of pain-related behavioral depression , 2013, Lab Animal.

[35]  Karl T. Schmidt,et al.  Effects of morphine on pain-elicited and pain-suppressed behavior in CB1 knockout and wildtype mice , 2011, Psychopharmacology.

[36]  Glenn W. Stevenson,et al.  Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice. , 2009, Life sciences.

[37]  K. Franklin,et al.  Improving the efficiency of the formalin test , 1999, PAIN®.

[38]  The Guide for the Care and Use of Laboratory Animals. , 2016, ILAR journal.